Cara Therpeutics' stock soared on 23 July after the company announced positive mid-stage results for its anti-itch medication.
The next-gen kappa opioid receptor agonist, CR845, hit its primary endpoint in a small Phase II study of patients with uremic pruritus, a chronic itching suffered by dialysis patients. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?